Granulomatous disease in common variable immunodeficiency

被引:102
作者
Morimoto, Y [1 ]
Routes, JA [1 ]
机构
[1] Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1007/s11882-005-0008-x
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Common variable immunodeficiency (CVID) is a primary immunodeficiency of unknown etiology characterized by low levels of immunoglobulin (Ig)G, failure to make specific antibodies in response to infection or immunization, and variable T-cell abnormalities. Multisystemic granulomatous disease is a well-documented complication of CVID, and its presence is associated with significant morbidity and early mortality. Although the lung is the most common organ system affected, granulomas are also found frequently in other organs, including skin, liver, spleen, and the gastrointestinal tract. Autoimmune disorders are common in these patients, and there appears to be an increased propensity to develop lymphoproliferative disorders. Common physical, radiographic, and laboratory abnormalities in patients with CVID and granulomatous disease include splenomegaly, hilar and mediastinal lymphadenopathy with ground glass or nodular opacities in the lung parenchyma, and reduced T-cell numbers and function. The etiology of granulomatous disease in patients with CVID is unknown, and optimal treatment of granulomatous disease in CVID remains to be established. Further studies are needed to elucidate the underlying etiology of granulomatous lymphoproliferative interstitial lung disease and to delineate appropriate treatments for this disease.
引用
收藏
页码:370 / 375
页数:6
相关论文
共 39 条
[1]  
Ameratunga R, 2000, PATHOLOGY, V32, P280
[2]  
[Anonymous], KATZENSTEINS ASKINS
[3]  
Ariatti C, 2001, Ann Ital Med Int, V16, P163
[4]   Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency [J].
Bates, CA ;
Ellison, MC ;
Lynch, DA ;
Cool, CD ;
Brown, KK ;
Routes, JM .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 114 (02) :415-421
[5]   Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency [J].
Busse, PJ ;
Razvi, S ;
Cunningham-Rundles, C .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 109 (06) :1001-1004
[6]   IDENTIFICATION OF HERPESVIRUS-LIKE DNA-SEQUENCES IN AIDS-ASSOCIATED KAPOSIS-SARCOMA [J].
CHANG, Y ;
CESARMAN, E ;
PESSIN, MS ;
LEE, F ;
CULPEPPER, J ;
KNOWLES, DM ;
MOORE, PS .
SCIENCE, 1994, 266 (5192) :1865-1869
[7]  
Cornejo P, 1999, BRIT J DERMATOL, V140, P546
[8]   Common variable immunodeficiency: Clinical and immunological features of 248 patients [J].
Cunningham-Rundles, C ;
Bodian, C .
CLINICAL IMMUNOLOGY, 1999, 92 (01) :34-48
[9]   Common variable immunodeficiency. [J].
Cunningham-Rundles C. .
Current Allergy and Asthma Reports, 2001, 1 (5) :421-429
[10]   Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency [J].
de Gracia, J ;
Vendrell, M ;
Alvarez, A ;
Pallisa, E ;
Rodrigo, MJ ;
de la Rosa, D ;
Mata, F ;
Andreu, J ;
Morell, F .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2004, 4 (06) :745-753